Summary:
The purpose of this study is to test whether two investigational drugs called CAD106 and CNP520, administered separately, can slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype.
Qualified Participants Must:
• Be between the ages of 60 and 75
•
Be Cognitively unimpaired
• Have a study partner
Qualified Participants May Receive:
May be compensated for time and travel.